GUIAS HIPERTENSION ARTERIAL.indb - Scc

242
GUÍAS COLOMBIANAS PARA EL DIAGNÓSTICO
Y TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL
Bibliografía
1. Turnbull F, Neal B, Algert C, et al. Blood Pressure Lowering Treatment Trialists´
Collaboration. Effects of different blood pressure-lowering regimens on major
cardiovascular events in individuals with and without diabetes mellitus: results of
prospectively designed overviews of randomized trials. Arch Intern Med 2005;
165: 1410-1419.
2. Getting a handle on obesity (editorial). Lancet 2002; 359: 1955.
3. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in
hypertensive patients treated with diuretics: a 14-year follow-up. Lancet 1982;
2: 1293-1295.
4. Dahlof B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an
antihipertensive regimen of amlodipine adding perindopril as required versus
atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet
2005; 366: 895-906.
5. Opie LH. Old antihypertensives and new diabetes. J Hypertens 2004; 22:
1453-1458
6. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of
new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-
969.
7. Chobanian AV, Bakris GL, Black HR, et al, and the National High Blood Pressure
Education Program Coordinating Committee. The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure. The JNC 7 report. JAMA 2003; 289: 2560-2572.
8. Julius PS, Kjeldsen PS, Weber M, et al. VALUE trial group. Outcomes in
hypertensive patients at high cardiovascular risk treated with regimens based
on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:
2022-2031.
9. Yusuf S, Gerstein H, Hoogwerf B, et al. For the HOPE Study Investigators. Ramipril
and the development of diabetes. JAMA 2001; 286: 1882-1885.
10. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beefers G, de Faire U, et al.
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan
Intervention For Endpoint reduction in hypertension study (LIFE): a randomised
trial against atenolol. Lancet 2002; 359: 1004-1010.
11. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting
enzyme inhibitor or calcium channel blocker versus diuretic: the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). JAMA 2002; 288: 2981-2990.
12. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in
the Elderly (SCOPE): principal results of a randomized double-blind intervention
trial. J Hypertens 2003; 21: 875-886.
13. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O.
Metabolic outcome during 1 year in newly detected hypertensives: results of
Revista Colombiana de Cardiología
Febrero 2007
the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy
Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
14. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination
treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme
inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled
tiral. Lancet 2003; 361: 117-124.
15. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce
peroxisome proliferator-activated receptor-{gamma} activity. Circulation 2004;
109: 2054-7.
16. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor
blockers in the metabolic syndrome. Circulation 2004; 110: 1507-1512.
17. Teo K, Yusuf S, Sleight P, et al; ONTARGET/TRANSCEND Investigators. Rationale,
design, and baseline characteristics of 2 large, simple, randomized trials
evaluating telmisartan, ramipril, and their combination in high-risk patients: the
Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint
Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with
Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;
148: 52-61.
18. Weiner IM, Mudge GH. Diuretics and other agents employed in the mobilization
of edema fluid. In: Gilman AG, Goodman LS, Rall TW, et al., editors. Goodman
and Gilman’s the pharmacological basis of therapeutics. New York: Macmillan
Publishing Co.; 1985. p. 895.
19. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure. National Heart,
Lung, and Blood Institute; National High Blood Pressure Education Program
Coordinating Committee. Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Hypertension 2003; 42: 1206-1252.
20. Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensinconverting
enzyme inhibition and angiotensin receptor blockade in hypertension.
Hypertension 2005; 45: 880-886.
21. Dahlof B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality
in Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a
randomized trial against atenolol. Lancet 2002; 359: 995-1003.
22. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N
Engl J Med 2001; 345: 861-869.
23. Lewis EJ, Hunsicker LG, Clark WR, et al. Renoprotective effect of the angiotensin-receptor
antagonist irbesartan in patients with nephropathy due to type 2
diabetes. N Engl J Med 2001; 345: 851-860.
24. Parving H-H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan
on the development of diabetic nephropathy in patients with type 2 diabetes. N
Engl J Med 2001; 345: 870-878.